MTAP and cancer: The discovery of MTA-uncompetitive PRMT5 inhibitors has galvanized drug discovery efforts to generate precision cancer medicines since MTA is elevated in many cancers due to deletion of MTAP, thereby exposing a synthetic lethal vulnerability.